Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

Table S5 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

<p>Statistics from DESeq2</p>

Saved in:

書目詳細資料
主要作者:	Alyssa C. Flint (16676029) (author)
其他作者:	Dana K. Mitchell (16676032) (author), Steven P. Angus (15084264) (author), Abbi E. Smith (16676035) (author), Waylan Bessler (16676038) (author), Li Jiang (16676041) (author), Henry Mang (15293185) (author), Xiaohong Li (16676044) (author), Qingbo Lu (16676047) (author), Brooke Rodriguez (16676050) (author), George E. Sandusky (16676053) (author), Andi R. Masters (16676056) (author), Chi Zhang (15084270) (author), Pengtao Dang (16676059) (author), Jenna Koenig (16676062) (author), Gary L. Johnson (15081520) (author), Weihua Shen (16676065) (author), Jiangang Liu (15018711) (author), Amit Aggarwal (16610489) (author), Gregory P. Donoho (16676068) (author), Melinda D. Willard (16676071) (author), Shripad V. Bhagwat (16676074) (author), D. Wade Clapp (16676077) (author), Steven D. Rhodes (16676080) (author)
出版:	2025
主題:	Cancer Molecular and Cellular Biology Therapeutic Research and Development Methods and Technology Cell Cycle CDKs and CDK inhibitors Chemotherapy Combination chemotherapy Gene Technologies High-throughput sequencing Preclinical Models Animal models of cancer Proteomics Rare Cancers Translational Research
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Table S2 from Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
由: Alyssa C. Flint (16676029)
出版: (2025)

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
由: Elizabeth R. Tucker (15053624)
出版: (2025)

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
由: Elizabeth R. Tucker (15053624)
出版: (2025)

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
由: Elizabeth R. Tucker (15053624)
出版: (2025)

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
由: Elizabeth R. Tucker (15053624)
出版: (2025)

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
由: Elizabeth R. Tucker (15053624)
出版: (2025)

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
由: Elizabeth R. Tucker (15053624)
出版: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
由: Arun Kanakkanthara (14937731)
出版: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
由: Arun Kanakkanthara (14937731)
出版: (2025)

Table S1 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
由: Xiaoqing Cheng (16918496)
出版: (2025)

Table S2 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
由: Xiaoqing Cheng (16918496)
出版: (2025)

Table S3 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
由: Xiaoqing Cheng (16918496)
出版: (2025)

Table S4 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
由: Xiaoqing Cheng (16918496)
出版: (2025)

Table S5 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
由: Xiaoqing Cheng (16918496)
出版: (2025)

Table S6 from Breast Cancer Mutations <i>HER2<sup>V777L</sup></i> and <i>PIK3CA<sup>H1047R</sup></i> Activate the p21–CDK4/6–Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance
由: Xiaoqing Cheng (16918496)
出版: (2025)

Supplementary Tables from Biallelic <i>Dicer1</i> Mutations in the Gynecologic Tract of Mice Drive Lineage-Specific Development of <i>DICER1</i> Syndrome–Associated Cancer
由: Yemin Wang (17315078)
出版: (2025)

Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
由: Aurelius Omlin (14971513)
出版: (2025)

Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer
由: Aurelius Omlin (14971513)
出版: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
由: Dwight H. Owen (15034782)
出版: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
由: Dwight H. Owen (15034782)
出版: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
由: Dwight H. Owen (15034782)
出版: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
由: Dwight H. Owen (15034782)
出版: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
由: Dwight H. Owen (15034782)
出版: (2025)

Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
由: Evangeline R. Jackson (15558808)
出版: (2025)

Supplementary Tables from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S1 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S1 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S1 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S1 page4 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S2 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S2 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S2 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S3 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S3 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S4 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S4 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S5 page1 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S5 page2 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Figure S5 page3 from Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i>Mutant Pancreatic Cancer
由: Craig M. Goodwin (14955973)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_nn9oarh9bt8hfb1o08jj6pid7g